INITIAL RESULTS OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH DOSE‐ADJUSTED R‐EPOCH FOR PATIENTS WITH RICHTER'S SYNDROME (CRC‐043). (12th June 2019) - Davids, M.S.